Melatonina
Anno: 2012
-
Riferimento:J Appl Toxicol. 2012 Dec;32(12):952-8.Azione della melatonina:Study on disruption of circadian rhythmicity in humans (children if possible) under long-term exposure to weak ELF MF.Target:Extremely low-frequency (ELF) magnetic fields (MF)
-
Riferimento:J Pineal Res. 2012 Apr;52(3):322-31.Azione della melatonina:Melatonin sensitizes human hepatoma cells to ER tress-induced apoptosis by down-regulating COX-2 xpression, incresing the levels of CHOP and decreaing the Bcl-2/Bax ratio.Target:Endoplasmin reticulum, Cyclooxygenase-2, Pro-apoptotic transcription factor.
-
Riferimento:Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):337-44.Azione della melatonina:Systemic effects of darkness and excessive melatonin synthesis enables cancer protection treatment for people living in light-deficient environment.Target:Racial/ethnic disparities
-
Riferimento:Oncol Rep. 2012 Aug;28(2):418-28.Azione della melatonina:Circadian system alteration and melatonin reduction, for exposure to light-at-night during night shift work, is the most valid hypotheses on the relation of shift work and breast cancer.Target:Night shift work
-
Titolo: A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkersRiferimento:Cancer Causes Control. 2012 Apr;23(4):609-16.Azione della melatonina:Effects of melatonin supplementation (3 mg oral melatonin, daily for 4 months) in postmenopausal breast cancer survivors.Target:Estradiol-lowering effects of melatonin.
-
Riferimento:Dig Dis Sci. 2012 Oct 10.Azione della melatonina:Supplementation by exogenous melatonin (20 and 40 mg/kg body weight) significantly reduces MTX-induced small intestinal damage.Target:Methotrexate (MTX).
-
Riferimento:Int J Cancer. 2012 May 30.Azione della melatonina:Sleep duration is not significantly associated with breast cancer risk reduction.Target:6-sulfatoxymelatonin (aMT6s)
-
Riferimento:Recent Pat Endocr Metab Immune Drug Discov. 2012 May;6(2):108-16. Review.Azione della melatonina:Based on its Selective Estrogen Receptor Modulator [SERM) and Selective Estrogen Enzyme Modulator (SEEM) properties. Its nocturnal suppression by light-at-night (LAN) has been considered a risk-factor for breast cancer.Target:Inhibiting activity of P450 aromatase.
-
Riferimento:Eur J Pharmacol. 2012 Apr 15;681(1-3):34-43.Azione della melatonina:Administration of melatonin with all-trans retinoic acid and somatostatin may be of significant therapeutic benefit in breast cancer.Target:Melatonin effects potentiated
-
Riferimento:Scand J Work Environ Health. 2012 Jul 1;38(4):380-90.Azione della melatonina:Elevations in risk of breast cancer after about 20 years working night shift. Accelerated tumor growth by suppression of melatonin secretion.Target:Shift work carcinogenic to humans (group 2A).